AltaThera Pharmaceuticals’ Post

Penumbra, Inc. announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash™ 2.0, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary emboli (PE). Lightning Flash 2.0 features advanced Lightning Flash algorithms, designed for increased speed and sensitivity to thrombus and blood flow. These new advancements combined with Penumbra’s novel catheter technology allow physicians to better navigate the body’s complex anatomy and deliver high power for clot removal with possible minimal blood loss. Read More: https://lnkd.in/dpa-TkyE “Based on what we’ve seen in the initial launch, Lightning Flash 2.0 has significantly improved procedure time by shortening the aspiration time. It has also shown reductions in blood removed during aspiration. These advantages can improve patient safety, provide better outcomes for the patients, and streamline efficiency for physicians treating the patients,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “As adoption of thrombectomy becomes more widespread, Lightning Flash 2.0 will provide physicians with the confidence that CAVT is a valuable frontline option.” “Lightning Flash 2.0 now combines an optimally sized catheter with the latest algorithm technology designed to more efficiently remove blood clots while maintaining a high level of safety,” said Adam Elsesser, president and chief executive officer of Penumbra #mededgemea #CAVT #MedicalTechnology #cardiology #vascularhealth #InnovativeTechnology #healthtech #hearthealth #cardiovascular #HealthcareNews #MedicalDevices #healthcareinnovation #patientcare #healthcaretechnology

It's a real honor to be invited to the Cardiovascular Clinical Trial (CVCT) meeting at the National Press Club in Washington DC. This is a unique meeting that brings together trialists, regulators, policy makers and developers to discuss important questions relating to cardiovascular innovation. I spoke about innovation and the current EU regulatory and HTA dynamics. Marco Marchetti provided an excellent update on the current status of the HTA Regulation in Europe and future plans for engagement between the EMA expert panels for MDR and joint scientific consultations for HTA. Alan Fraser provided an excellent update on the CORE-MD Project. There is simply a plethora of innovation supports now offered by US FDA with the breakthrough device program, the TAP (total product lifecycle advisory program) and the earrly feasibility program to name just a few. Hearing from both regulators and product developers about the value of regular interaction and problem solving, whilst maintaining the same independence and impartiality of regualtory decision making is vital if we want to ensure that 'high risk, high reward' innovations can translate from idea to practice. This dynamic is not one we currently have in Europe, however it is something I think we need to really prioritise to implement the MDR with fidelity. If we want to get there, we need trust, good scientific methods, transparency and a determination to move beyond a binary - 'this complies and this doesn't' mindset. https://lnkd.in/efDkF5AM #mdr #medicaldevices #innovation #cardiology

Over the last few weeks, we've featured the different tracks from which you can choose to participate at the Medtech Impact Symposium on March 28. Today, we are featuring the last (but certainly not least!) of the four breakout tracks: ️Diabetes. Our Diabetes Track will look at the evolution of diabetes care, particularly how medical technology has improved the management and monitoring of the condition. From the advent of CGM’s to the impact of GLP-1’s on the medical device industry, this track will discuss not only how technology is treating diabetes but the potential to reverse the root causes of the disease. We’ll begin with a focus on technology that enables the measurement of disease. In our second session, we’ll discuss interventions that treat the progression of the disease including surgical solutions. During our last panel, we’ll discuss how medical technology can improve the ongoing maintenance of the disease, as well as proactively reduce complications. Hear from industry leaders including: Holly Scott, Vice President and Senior Partner, The Mullings Group, Yael Glassman, Vice President of Business Development and Strategy, Diabetes, Medtronic, Chris Wells, PhD, Principal, Commercial Strategy Consulting, Clarivate, Jay Caplan, Co-Founder and President, Fractyl Health, Joe Virgillo, CEO, Morphic Medical, Stacey Pugh, CEO, Endogenex, Caroline Irungu, MPA, Global Commercial Strategy – MedTech, Dassault Systèmes, Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Medical Director, Insulet Corporation, Jon Bloom, MD, CEO, Podimetrics, Henrik Bengtsson, Senior Innovation Manager, Novo Nordisk and Jessica Lavoie, Head of US Marketing, Healthy.io. Learn more and grab your tickets at https://lnkd.in/ekw9vB29 Use code "DTRACK" (no quotes) to save $100! Don't delay, registration for the Symposium closes on March 22 at 5:00 pm ET! #medtechimpact #diabetes #symposium #Innovationinhealth #medtech #cgm #GLP-1 #medicaldevices #monitoring #surgical #maintenance #reducecomplications

Wondering what's HOT the world of #thrombosis? Check out October's edition of What's Hot In Clots, our monthly digest on key updates, covered by our Medical Advisory Board member Behnood Bikdeli! This month covers findings around #abelacimab, electronic alerts, #bivalirudin vs #heparin based periprocedural anticoag, & more. Check it out at https://lnkd.in/e4_nCZe7

Episode 2 of Beyond the Chart with Dr. Dash is now live! 🎙 In this episode, Rajesh Dash MD PhD engages in an insightful conversation with Bethany Kalich, a clinical pharmacist and the U.S. Cardiovascular Medical Director at Amgen. Together, they explore the ambitious health goals set for 2030 and the collaborative efforts required to make significant strides in cardiovascular health. 🔎 Key Topics Covered: - Ambitious Health Goals for 2030: Cutting cardiovascular events in half by 2030 through system-wide collaboration across healthcare providers and pharmaceutical partners. - Increasing LDL Testing Rates: Doubling LDL cholesterol testing rates as a critical early milestone in improving cardiovascular health. - Implementation Science and Quality Measures: Advancing LDL testing and goal achievement through the Lattice consortium, focusing on quality measures for enhanced care. - Addressing Disparities in Healthcare: Ensuring equitable access to healthcare interventions for groups with higher cardiovascular disease burdens. Tune in to learn more about the role of technology, real-world evidence, and systemic collaboration in shaping the future of healthcare. 🎧 Listen now: https://lnkd.in/gfZQYNvV #cardiovascularhealth #cardiology #healthcareinnovation #medicaleducation #clinicalops #clinicaltrials #clinicalcare #clinicalintelligence #healthtech

Evidence based

SAVE THE DATE: A4M (The American Academy of Anti-Aging Medicine) LongevityFest 2023 Las Vegas, NV December 14-16, 2023 Stop by Microbiome Labs's booth at A4M's 31st Annual World Congress in December (14th-16th). We'll be at the world's largest Anti-Aging conference, LongevityFest 2023: Leveling Up Healthcare, focusing on longevity and healthcare. Join us for these presentations: Sponsored Breakfast (NON-CME) Speaker: Ted Dinan, MD 12/14/23 | 6:30 a.m. | 1 hour Endocrine Module (NON-CME) Speaker: Eamonn Quigley, MD 12/16/2023 | 8:30 a.m. | 30 minutes General Session (CME) Lacey Hall, RD 12/15/23 | 3:30 p.m. | 30 minutes This industry-disrupting medical education event is the ultimate gathering of clinicians, researchers, and innovators, all dedicated to exploring the cutting-edge of longevity and healthcare. We hope to see you in Las Vegas at A4M's LongevityFest 2023. Register today: [https://lnkd.in/gheeDrW2] #AntiAgingPractices #AntiAgingSupport #RegenerativeSupport #LongevitySupport #A4M #AmericanAcademyofAntiAgingMedicine #LongevityFest #MicrobiomeLabs **This information is presented for educational purposes only. These statements have not been evaluated by the Food and Drug Administration (FDA) and are offered as information only. Microbiome Labs does not endorse or make claims about the sponsors’ information, products, processes, and/or practices.

Dr. Erin Michos shares The New Promise of CETPi, featuring an explanation of the mechanism, previous history, and the next generation of #CETP inhibitors--which starts with obicetrapib. Get up to speed in this 10-minute education segment from PACE-CME: Physicians' Academy for Cardiovascular Education. https://bit.ly/4bpvgBs

#MannKind #INHALE-3 study results are ready to present! Find out from the BEST leaders in the field of Diabetes Irl Hirsch and #RoyBeck! see below for details! ⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️

The EffPac trial was a prospective, multicentre, randomised controlled trial (RCT) that enrolled 171 patients of Rutherford category two to four with medium-length femoropopliteal lesions. Patients were allocated 1:1 to either Luminor drug-coated balloon (DCB) angioplasty or plain balloon angioplasty (POBA). The long-term results showed a high efficacy (fTLR 82.1%) and statistically superior primary patency for Luminor over POBA, and importantly, showed that DCB use resulted in no safety differences between the two groups. The investigators achieved on-site patient visits in 50% of the recruited patients after five years. “These data are pretty rare […] and actually after this whole discussion about safety of paclitaxel-coated DCBs, I think [this trial] really adds important data,” Prof. Dr. Ulf Teichgräber (Jena, Germany) tells Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023 annual meeting. This video is sponsored by iVascular https://lnkd.in/etEv2dzm #EffPac #DCB #femoropoplitea #endovascular